Allosteric modulation of G protein-coupled receptors

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

G protein-coupled receptors (GPCRs) constitute the largest receptor superfamily in the human genome and represent the most common targets of drug action. Classic agonist and antagonist ligands that act at GPCRs tend to bind to the receptor's orthosteric site, that is, the site recognized by the endogenous agonist for that receptor. However, it is now evident that GPCRs possess additional, extracellular, allosteric binding sites that can be recognized by a variety of small molecule modulator ligands. Allosteric modulators offer many advantages over classic orthosteric ligands as therapeutic agents, including the potential for greater GPCR-subtype selectivity and safety. However, the manifestations of allosterism at GPCRs are many and varied and, in the past, traditional screening methods have generally failed to detect many allosteric modulators. More recently, there have been a number of major advances in high throughput screening, including the advent of cell-based functional assays, which have led to the discovery of more allosteric modulator ligands than previously appreciated. In addition, a number of powerful analytical techniques have also been developed exclusively for detecting and quantifying allosteric effects, based on an increased awareness of various mechanisms underlying allosteric modulator actions at GPCRs. Together, these advances promise to change the current paucity of GPCR allosteric modulators in the clinical setting and yield novel therapeutic entities for the treatment of numerous disorders.

Original languageEnglish
Pages (from-to)2003-2013
Number of pages11
JournalCurrent Pharmaceutical Design
Volume10
Issue number17
DOIs
Publication statusPublished - 2004
Externally publishedYes

Keywords

  • Allosteric interaction
  • Cooperativity
  • Dissociation kinetics
  • G protein-coupled receptor
  • High throughput screening
  • Mathematical modeling
  • Radioligand binding
  • Ternary complex model

Cite this

@article{45acf8cf2c1745cd943e31ac9ae1a2d2,
title = "Allosteric modulation of G protein-coupled receptors",
abstract = "G protein-coupled receptors (GPCRs) constitute the largest receptor superfamily in the human genome and represent the most common targets of drug action. Classic agonist and antagonist ligands that act at GPCRs tend to bind to the receptor's orthosteric site, that is, the site recognized by the endogenous agonist for that receptor. However, it is now evident that GPCRs possess additional, extracellular, allosteric binding sites that can be recognized by a variety of small molecule modulator ligands. Allosteric modulators offer many advantages over classic orthosteric ligands as therapeutic agents, including the potential for greater GPCR-subtype selectivity and safety. However, the manifestations of allosterism at GPCRs are many and varied and, in the past, traditional screening methods have generally failed to detect many allosteric modulators. More recently, there have been a number of major advances in high throughput screening, including the advent of cell-based functional assays, which have led to the discovery of more allosteric modulator ligands than previously appreciated. In addition, a number of powerful analytical techniques have also been developed exclusively for detecting and quantifying allosteric effects, based on an increased awareness of various mechanisms underlying allosteric modulator actions at GPCRs. Together, these advances promise to change the current paucity of GPCR allosteric modulators in the clinical setting and yield novel therapeutic entities for the treatment of numerous disorders.",
keywords = "Allosteric interaction, Cooperativity, Dissociation kinetics, G protein-coupled receptor, High throughput screening, Mathematical modeling, Radioligand binding, Ternary complex model",
author = "May, {L. T.} and Avlani, {V. A.} and Sexton, {P. M.} and Arthur Christopoulos",
year = "2004",
doi = "10.2174/1381612043384303",
language = "English",
volume = "10",
pages = "2003--2013",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers",
number = "17",

}

Allosteric modulation of G protein-coupled receptors. / May, L. T.; Avlani, V. A.; Sexton, P. M.; Christopoulos, Arthur.

In: Current Pharmaceutical Design, Vol. 10, No. 17, 2004, p. 2003-2013.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Allosteric modulation of G protein-coupled receptors

AU - May, L. T.

AU - Avlani, V. A.

AU - Sexton, P. M.

AU - Christopoulos, Arthur

PY - 2004

Y1 - 2004

N2 - G protein-coupled receptors (GPCRs) constitute the largest receptor superfamily in the human genome and represent the most common targets of drug action. Classic agonist and antagonist ligands that act at GPCRs tend to bind to the receptor's orthosteric site, that is, the site recognized by the endogenous agonist for that receptor. However, it is now evident that GPCRs possess additional, extracellular, allosteric binding sites that can be recognized by a variety of small molecule modulator ligands. Allosteric modulators offer many advantages over classic orthosteric ligands as therapeutic agents, including the potential for greater GPCR-subtype selectivity and safety. However, the manifestations of allosterism at GPCRs are many and varied and, in the past, traditional screening methods have generally failed to detect many allosteric modulators. More recently, there have been a number of major advances in high throughput screening, including the advent of cell-based functional assays, which have led to the discovery of more allosteric modulator ligands than previously appreciated. In addition, a number of powerful analytical techniques have also been developed exclusively for detecting and quantifying allosteric effects, based on an increased awareness of various mechanisms underlying allosteric modulator actions at GPCRs. Together, these advances promise to change the current paucity of GPCR allosteric modulators in the clinical setting and yield novel therapeutic entities for the treatment of numerous disorders.

AB - G protein-coupled receptors (GPCRs) constitute the largest receptor superfamily in the human genome and represent the most common targets of drug action. Classic agonist and antagonist ligands that act at GPCRs tend to bind to the receptor's orthosteric site, that is, the site recognized by the endogenous agonist for that receptor. However, it is now evident that GPCRs possess additional, extracellular, allosteric binding sites that can be recognized by a variety of small molecule modulator ligands. Allosteric modulators offer many advantages over classic orthosteric ligands as therapeutic agents, including the potential for greater GPCR-subtype selectivity and safety. However, the manifestations of allosterism at GPCRs are many and varied and, in the past, traditional screening methods have generally failed to detect many allosteric modulators. More recently, there have been a number of major advances in high throughput screening, including the advent of cell-based functional assays, which have led to the discovery of more allosteric modulator ligands than previously appreciated. In addition, a number of powerful analytical techniques have also been developed exclusively for detecting and quantifying allosteric effects, based on an increased awareness of various mechanisms underlying allosteric modulator actions at GPCRs. Together, these advances promise to change the current paucity of GPCR allosteric modulators in the clinical setting and yield novel therapeutic entities for the treatment of numerous disorders.

KW - Allosteric interaction

KW - Cooperativity

KW - Dissociation kinetics

KW - G protein-coupled receptor

KW - High throughput screening

KW - Mathematical modeling

KW - Radioligand binding

KW - Ternary complex model

UR - http://www.scopus.com/inward/record.url?scp=3042557815&partnerID=8YFLogxK

U2 - 10.2174/1381612043384303

DO - 10.2174/1381612043384303

M3 - Review Article

VL - 10

SP - 2003

EP - 2013

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 17

ER -